Combination Therapy
for Joint Pain Relief

Patented Technology Designed
to Address Significant Unmet
Medical Needs

Single Injection Combining
Two Proven Therapies


April 14, 2015
Carbylan Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 8, 2015
Carbylan Therapeutics, Inc. Announces Pricing of Initial Public Offering

December 30, 2014
Carbylan Therapeutics Expands Board of Directors with Three Appointments

July 25, 2011
Carbylan BioSurgery Announces Positive Clinical Trial Results for Hydros-TA in Patients with Pain from Knee Osteoarthritis

January 5, 2011
BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros-TA in Patients with Pain from Knee Osteoarthritis; Core Patent Issued

November 26, 2007
Announces $20 Million Series B Financing

Carbylan Therapeutics Technology

Carbylan Therapeutics technology includes drug/device combination products under development based on novel, chemically engineered polymer systems incorporating hyaluronic acid, a well-known polysaccharide widely present in the human body.

Learn More